Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 3770039)

Published in Eur J Cancer Clin Oncol on July 01, 1986

Authors

J Klastersky, P Mommen, F Cantraine, A Safary

Articles by these authors

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med (1998) 13.94

Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis (1974) 5.47

Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med (2000) 4.74

The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med (1999) 3.93

Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother (1972) 3.21

Carbenicillin and hypokalemia. Ann Intern Med (1973) 2.83

Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ (1992) 2.76

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer (2000) 2.51

Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci (1977) 2.28

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol (1995) 2.28

Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med (1984) 2.17

Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother (1986) 2.12

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03

Protection against hepatitis A by an inactivated vaccine. JAMA (1994) 1.99

Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis (1978) 1.89

Cephradine. Antibacterial activity and clinical effectiveness. Chemotherapy (1973) 1.88

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology (1998) 1.84

Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis (1981) 1.78

Comparison of amikacin and gentamicin. Clin Pharmacol Ther (1975) 1.73

Antipseudomonal drugs: comparative study of gentamicin, sisomicin and tobramycin in vitro and in human volunteers. Eur J Cancer (1973) 1.64

Antimicrobial activity of the carbenicillin-gentamicin combination against gram-negative bacilli. Am J Med Sci (1970) 1.62

Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis (1982) 1.62

Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother (1979) 1.62

Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis (1992) 1.61

Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis (1986) 1.59

Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest (1972) 1.55

Infections caused by Providence bacilli. Scand J Infect Dis (1974) 1.49

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol (1989) 1.48

Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin. Am J Med Sci (1973) 1.48

Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother (1975) 1.43

Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin. Antimicrob Agents Chemother (1986) 1.43

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother (1984) 1.41

Bacteriophage types and antibiotic susceptibility of Staphylococcus aureus. Appl Microbiol (1971) 1.40

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol (1999) 1.40

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer (1997) 1.40

Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther (1976) 1.39

Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol (1988) 1.38

Immunogenicity of inactivated hepatitis A vaccine in children. Gastroenterology (1993) 1.38

Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. JAMA (1974) 1.38

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine (1990) 1.35

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics (1985) 1.34

Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis (1983) 1.33

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31

Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother (1983) 1.29

Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol (1984) 1.28

Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis (1995) 1.25

Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol (1975) 1.24

Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother (1987) 1.23

Pneumonia caused by gram-negative bacilli in hospitalized patients presenting malignant disease. Eur J Cancer (1971) 1.22

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med (1987) 1.21

Effect of mixing on rifampin bactericidal activity against staphylococci. Antimicrob Agents Chemother (1981) 1.21

Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer (1973) 1.20

Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum. J Infect Dis (1976) 1.20

Ascending myelitis in association with herpes-simplex virus. N Engl J Med (1972) 1.20

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother (1996) 1.19

Prophylactic antibiotics in oral, pharyngeal and laryngeal surgery for cancer: (a double-blind study). Laryngoscope (1973) 1.19

Antimicrobial effectiveness ofkanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods. J Med Microbiol (1974) 1.19

Lactic acidosis: a metabolic complication of extensive metastatic cancer. Eur J Cancer Clin Oncol (1983) 1.18

Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin. Antimicrob Agents Chemother (1986) 1.17

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother (1986) 1.17

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J (1992) 1.16

Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med (1971) 1.16

Factors that influence cancer patients' anxiety following a medical consultation: impact of a communication skills training programme for physicians. Ann Oncol (2006) 1.16

Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. J Antimicrob Chemother (1986) 1.15

Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother (1983) 1.12

Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother (1974) 1.12

Anaerobic wound infections in cancer patients: comparative trial of clindamycin, tinidazole, and doxycycline. Antimicrob Agents Chemother (1977) 1.10

Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer (1994) 1.10

Clinical and bacteriological evaluation of netilmicin in gram-negative infections. Antimicrob Agents Chemother (1977) 1.10

Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J (1987) 1.10

A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol (2009) 1.08

Comparative study of tobramycin and gentamicin with special reference to anti-pseudomonas activity. Clin Pharmacol Ther (1973) 1.07

Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol (1983) 1.07

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA (1989) 1.07

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine (1998) 1.07

Boosting properties of recombinant DNA hepatitis B vaccine. Lancet (1986) 1.07

Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Med (1987) 1.04

Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest (1979) 1.03

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother (1991) 1.03

Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J (1993) 1.03

Cognitive recovery in idiopathic normal pressure hydrocephalus: a prospective study. Neurosurgery (1994) 1.02

Bacteriological evaluation of minocycline, a new tetracycline. Chemotherapy (1972) 1.02

The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J (1991) 1.02

Effectiveness of erythromycin plus alkalinization and of nitrofurantoin in the treatment of urinary tract infections. Curr Ther Res Clin Exp (1971) 1.02

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol (1986) 1.02

In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem. J Antimicrob Chemother (1987) 1.01

Therapy of small cell lung cancer: anything new? Eur J Cancer Clin Oncol (1988) 1.01

Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol (1994) 1.00

Use of carbenicillin and polymyxin B for therapy of gram-negative bacilli infections. Chemotherapy (1971) 1.00

Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans. Antimicrob Agents Chemother (1976) 0.99

Comparison of sisomicin and gentamicin in bacteriuric patients with underlying diseases of the urinary tract. Antimicrob Agents Chemother (1975) 0.99

Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed (1997) 0.99

Comparative in vitro activities of temocillin and cefazolin against Klebsiella pneumoniae. Antimicrob Agents Chemother (1982) 0.99

Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine (1998) 0.98

Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis. Infection (1980) 0.98

Quantitative evaluation of polysomes and ribosomes by density gradient centrifugation and electron microscopy. Anal Biochem (1971) 0.98